Keyword: Samsung Biologics
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate...
In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development...
Markets & Companies
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
Samsung Biologics has agreed to buy out partner Biogen’s share of their Samsung Bioepis joint venture for up to $2.3 billion. The South Korean group said the deal will...
- GlaxoSmithKline has agreed an eight-year, $231 million, pact with South Korean CDMO Samsung Biologics to scale up manufacturing of biologics. The capacity Samsung provides will be...
Strategy & Management
- The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious...
- The digital developments in the healthcare industry, combined with an aging population and enormous scientific progress, pose new challenges for pharmaceutical companies. On the...